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Background: Gabapentin (GPN) is effective in reducing
post-operative pain and opioid consumption, but its
effects with regional anesthesia for total hip arthroplasty(THA) are not known. We designed this study to deter-
mine whether (1) gabapentin administration reduces pain
and opioid use after THA using a multimodal analgesic
regimen including spinal anesthesia; (2) pre-operative
administration of gabapentin is more effective than post-
operative administration.
Methods: After REB approval and informed consent, 126
patients were enrolled in a double-blinded, randomized-
controlled study. Patients received acetaminophen 1g per
os (p.o.), celecoxib 400mg p.o. and dexamethasone 8mg
intravenously, 1-2h pre-operatively. Patients were ran-
domly assigned to one of three treatment groups (G1:
Placebo/Placebo; G2: GPN/Placebo; G3: Placebo/GPN).
Patients received gabapentin 600mg (G2) or placebo (G1
and G3) 2 h before surgery. All patients had spinal anesthe-
sia [15 mg (3cc) of 0.SVo hypobaric bupivacaine with 10 pg
of fentanyll. In the post-anesthetic care unit, patients
received gabapentin 600mg (G3) or placebo (G1 and G2).
On the ward, patients received acetaminophen 1000mg
p.o. q6h, celecoxib 200mg p.o. q12h and a morphine PCA
device. Patients were interviewed 6 months post-surgery
to determine the incidence and severity of chronic post-
surgical pain.
Results: Mean * SD cumulative morphine (mg) consump-
tion (Gl = 49.4 t 24.8, G2: 47.2 130.1 and G3 : 56.1 t
38.2) at 48h and pain scores at 1.2,24,36 and 48h post-
surgery were not significantly different among the groups
lGr (n : 38), G2 (n:38) and G3 (z : 38)1. Side effect pro-
files were similar across groups. Six months after surgery,
the number of patients who reported chronic post-surgical
pain (G1 :1.0, G2: '1.2 and G3 : 9) and the severity of the
pain (G1 : 4.2 t 2.9, G2 : 4.L * 2.2 and G3 : 4.9 + 2.2) did
not differ significantly among the groups (P > 0.05).
Conclusions: A single 600 mg dose of gabapentin given
pre-operatively or post-operatively does not reduce mor-
phine consumption or pain scores in hospital or at 6
months after hip arthroplasty within the context of spinal
anesthesia and a robust multimodal analgesia regimen.
foral hip arthroplasty (THA) is associated withI significant pain and decreased mobilify in the
immediate post-operative period. Moderate to se-
vere post-operative pain is a frequent occurrence
after many surgeries."'Pain of this magnitude has
been shown to interfere with post-operative reha-
bilitation, discharge from hospital, and to lead to
the development of chronic pain in 3-35Vo of hip
arthroplasty patients." The addition of gabapentin,
a non-opioid medication, is effective in reducing
post-operative pain, opioid consumption and ac-
celerating_ functional recovery in other types of
surgery.*
Gabapentin, a structural analogue of y-amino
butyric acid, has been used as an anticonvulsant
and antinociceptive drug. Its main binding site is
the a-2-6 subunit of voltage-dependent calcium
channels.T The side effects of gabapentin tend to
be mild, with somnolence (20%), dizziness (187"),
ataxia (1.3%) and fatigue (11Vo) being the most
common.s Over the past B years, mant trials have
examined the efficacy of gabapentin for the treat-
ment of acute post-surgical pain. The surgical
populations studied include abdominal or pelvic
iuigery,n''-l 5 musculoskeletal surgerv5'16-22^ head
u ttdtt".k su r gery,23-2s b rea st 
"u, 
gur"y,'6 -'e va ri coc ele
surgery,3o thoracic surgery3t and recently cardiac
surgery." Of these randomized-controlled trials,
most consisted of a single dose of gabapentin given
before surgery. Only four of the above trials failed
to demonstrate a decrease in pain scores or an
opioidlp,linq effect in the early post-surgical
perlod.--'-"'-''-"
In the clinical setting, post-surgical pain is iiiflu-
enced by at least two factors: the inflammatory
response, which is the consequence of trauma to
peripheral tissues (i.e. surgical incision, dissection,
burns), and intra-operative nerve damage arising
from nerve transection, crushing or other nerve
injury.3!35 Both factors result in long-term changes
in the sensitivity of the central nervous system
that amplify the peripheral signal either by excita-
tory or by disinhibitory mechanisms. It is now
accepted that while general anesthesia may attenu-
ate transmission of afferent injury barrage from the
periphery- to the spinal cord and brain, it does not
block it.'o Moreover, systemic opioids may not
provide a sufficiently dense blockade of spinal
nociceptive neurons to prevent central sensitiza-
tion."' The processes leading to sensitization of
dorsal horn neurons are largely unaffected by
general anesthesia or routine doses of opioids.
Gabapentin has been extensively studied in general
anesthesia paradigms; however, few studies have
examined its possible preemptive effect when re-
gional anesthesia is used as the primary surgical
modalitv.'o''o
Preventive analgesia has evolved from preemp-
tive analgesia by reducing the importance of block-
ing solely noxious pre-operative stimuli.3aSe'ao Tyr"
emphasis is on preventing or obtunding the per-
ipheral nociceptive barrage and central sensitiza-
tion that arise throughout the entire peri-operative
period and not simply on blocking pre-operative
noxious afferent input. A preventive analgesic
effect is demonstrated when post-operative pain
and/or analgesic consumption is reduced relative
to another intervention, as long as the effect is
observed at a point in time that exceeds the clinical
duration of action of the target agent. One ap-
proach to ascertaining the outer limit of the clinical
duration of action of the target agent is to assess
pain and analgesic consumption at time points
>5.5 half-lives of the pharmacologic interven-
tion.al
In order to facilitate the translation of research
into clinical practice, it is important that trials
mirror clinical practice. Multimodal analgesia is
becoming the standard of practice in most institu-
tions. This practice involves the use of different
classes of analgesic agents with different routes of
administration to' provide superior pain relief at
rest and after movement'reduce opioid consump-
tion and3 reduce analgesic-related adverse ef-
fects.a'a3 Although mitty clinical trials have
demonstrated the effectiveness of multimodal an-
algesia, positive.r-esults may not translate into
clinical practice.*'*' This trial was designed to
evaluate the efficacy of gabapentin in the context
of a multimodal regimen including pre-operative
spinal anesthesia (bupivacaine), a COX-2 antago-
nist (celecoxib), acetaminophen and a steroid (dex-
amethasone). Although single-agent therapy may
attenuate the central nociceptive processing, multi-
modal therapy is more effective, and may be
associated with fewer side effects compared with
the high-dose, single-agent therap y.*'nf
More specifically, the novel aspects of this study
were to determine whether (1) a 600mg dose of
gabapentin, added to a robust multimodal analge-
sia regimery further reduces pain and opioid use
after THA under spinal anesthesia; (2) a 600mg
dose of gabapentin is more effective before vs. after
surgery (i.e. a preemptive effect); and (3) this
intervention leads to any difference in the inci-
dence and severity of chronic pain at 6 months (i.e.
a preventive effect).
Materials and methods
Patient sample and recruitment procedures
The study was approved by the hospital's Research
Ethics Board and all patients gave informed, writ-
ten consent to participate. The CONSORT guide-
lines were followed (i.e. statement for improving
the quality of reports of parallel-group randomized
trials) with respect.to the reporting of this rando-
mized control trial.*o Patients between the ages of
18 and 75 with an ASA physical status score of I,II
or III undergoing THA were eligible for this study.
Patients were not eligible if they had a known
allergy to any of the medications being used, a
history of drug or alcohol abuse, a history of being
on chronic pain medications (i.e. slow-release pre-
parations of opioids), rheumatoid arthritis, a psy-
chiatric disordeX, a history of diabetes with
impaired renal function, a body mass index (BMD
of >45 or patients unable or unwilling to use
patient-controlled analgesia. (PCA).
Patients were recruited at their pre-operative
assessment visit approximately 1,-2 weeks in
advance of their surgery. All subjects were
screened, and the study protocol, the use of the
PCA pump and the visual analogue pain scale
(VAS), a 10cm scale (with endpoints labeled 'no
pain' and 'worst pain possible'), were explained.
- D ru g pr epar ation, disp ensing and randomization
Gabapentin and placebo medications were encap-
sulated in identically colored gelatin capsules and
packaged in identical individual blister packs by
the Sunnybrook Health Sciences Centre Investiga-
tional Pharmacy in order to maintain double-blind
conditions. The placebo pills contained a mixture
of 50Vo cellulose and 507o lactose monohydrate. A
computer-generated randomization schedule was
used to assign patients at random in blocks of six to
one of the three treatment groups. The schedule
was created by the hospital investigational phar-
macy, which was otherwise not involved in the
clinical care of the patients or in the conduct of the
trial. The randomization schedule was kept in the
pharmacy and none of the investigators had access
to it. The pharmacy dispensed the capsules accord-
ing to the randomization schedule when the in-
vestigators informed them that a patient had been
recruited into the trial.
Pre-, intra- and post-operatire procedures
On the day of surgery/ all patients received acet-
aminophen 1000 mg per os (p.o.), celecoxib 400 mg
p.o. and dexamethasone 8 mg intravenously (i.v.),
1-2 h pre-operatively. Patients were randomly as-
signed to one of three treatment groups (G1:
Placebo/Placebo; G2: GBP /Placebo; and G3: Pla-
cebo/GBP). Group 2 received gabapentin 600mg
p.o. 2 h before surgery; the other groups received
an identical-looking placebo capsule.
All patients were prepared for surgery in a
specialized block area. Using an 18 g i.v. cannula,
the anesthetist started an i.v. infusion of Lactated
Ringer's solution. Blood pressure, ECG and oxime-
try monitors were applied. Midazolam L-3mg i.v.
was administered to achieve anxiolysis. Spinal
anesthesia was performed in the lateral decubitus
or sitting position. After subcutaneous infiltration
with lidocainel.Vo, and using a midline approach, a
25-G Whitacre needle (Beckton Dickinson and
Company, Franklin Lakes, NJ, USA) was inserted
at the L34, L4-5 or L5-S1 interspace, with the
aperture directed to the side of surgery. When free
flow of CSF was obtained, 15mg of.O.5Vo hypobaric
bupivacaine with L0 pg of fentanyl was injected. In
all groups, the total volume injected into the sub-
arachnoid space was 3.2m1, with aspiration at the
end of injection to ensure that the entire drug was
injected intrathecally. The patient was then placed
in the lateral decubitus position with the side of
surgery uppermost. Patients were then transferred
to the operating room/ where monitors were re-
applied, supplemental oxygen was provided and
sedation was administered by an i.v. propofol
infusion (25-100 mcg/kg/min) until the end of
surgery. The attending anesthesiologist was not
involved in the patients' evaluation post-opera-
tively.
Upon arrival to the recovery room, group 3
received gabapentin 600mg p.o.; the other groups
received an identical-looking placebo capsule. At
the time of PCA hookup in the post-anesthetic care
unit (PACU) (0 h) and every 4 h for the next 48 h,
patients were asked to record their pain intensity
at rest and after movement using a 10 cm VAS. The
PCA pump was set to deliver morphine at 1mg
per demand with a S-min lockout and no back-
ground infusion. All patients were instructed to
maintain their VAS pain score <4/10.If the VAS
pain score at rest was 5 cm or greater on two
consecutive 4-hourly assessments, the dose of i.v.
PCA morphine was increased to 1.5mg per de-
mand. At each time point after pain was measured,
patients were assessed for the incidence and se-
verity of sedation, nausea, vomiting and pruritus.
On post-operative day 1., movement-evoked pain
was measured in a standardized manner by asking
patients to rate their pain on a VAS after moving
from a lying to a sitting position at the edge of
the bed.
Patients were followed up by telephone 6
months after surgery. A maximum of three calls
were made and a voice message was left on the
third call. Patients were considered lost to follow-
up if they could not be reached and did not return
the call. Patients were administered three ques-
tionnaires: a follow-up Hip Arthroplasty.^ Pain
questionnaire, The Neuropathic Pain Scale"' and
The Hospital Anxiety and Depression Scale.s0 Pain
intensity was measured using a numeric rating
scale (NRS). The NRS consists of a series of num-
bers ranging from 0 to 10, with endpoints repre-
senting the most extreme pain experiences (0: no
pain and 10: worst possible pain). The NRS has
been shown to have good reliability and validity
and is sensitive to change following a pharmaco-
logical intervention.sl
Sample size estimate
In order to determine the number of patients to
recruit, data were collected from retrospective
chart reviews because we were unable to find a
published study e:amining the effect of gabapentin
on pain or morphine consumption in the hip
arthroplasty population. After identifying a small
subset of chartsJhat resembled the study popula-
tion (i.e. used a similar anesthetic technique with
and without gabapentin), we extracted cumulative
PCA morphine consumption. The patients who
were given gabapentin before surgery (n:'10)
used 19.06 t1,9.9mg [meanAstandard deviation(SD)l in the first 24h after surgery. The post-
operative gabapentin group (n:6) (i.e. adminis-
tered on arrival in the PACU but not before) used
34.8+13.1mg (mean+SD) in the first 24h after
surgery. This study was powered to detect a dif-
ference between patients who received pre-opera-
tive gabapentin vs. post-operative gabapentin.
Using the means and standard deviations from
our chart review, we determined that 30 subjects
per arm (n :90) would provide 95Vo power at an or,
set at 0.05 to detect a difference of 15.8mg of
morphine consumption between the patients who
received gabapentin pre-operatively vs. in the
PACU.
Statistical analysis
Data were analyzed using Statistical Analysis Soft-
ware (SAS for Windows, version 9.1, SAS Institute
Inc., Cary, NC). Demographic data and clinical
variables were compared using the non-parametric
Kruskal-Wallis test for the continuous and Fisher's
exact test for the categorical variables.
Morphine consumption Morphine consumption,
measured at four time points (1,2, 24, 36 and 48 h
post-surgery), was analyzed by a mixed model
(PROC MIXED) ANOVA. The model used an
autoregressive correlation structure within subjects
that decreases with increasing time lag between
measures/ and an inter-subject random effect of
differences between subjects. Group, time and
interaction effects were tested with the model.
The presence of a significant interaction effect
would suggest a difference in the rates of con-
sumption among the three groups.
VAS pain scores. VAS pain scores at rest and after
reported movement, measured at 1,2-,24-,36- and
48-h time points, were analyzed by a mixed model
ANOVA as above. The empirical distribution of the
scores was investigated visually using histograms,
and the deviation of the normality assumption of
the models was not considered significant. Post-
operative days2 1 VAS pain scores while the patient
moved from lying to sitting were compared be-
tween groups using non-parametric Kruskal-
Wallis test.
Adaerse effects. Sedation, nausea, vomiting, pruri-
fus and dizziness were assessed across the 48-h
period. Scores were calculated as the proportion of
the time points (where a non-missing value was
measured) at which the patient experienced the
specific adverse effect. Patients were then classified
based on the number of times the specific adverse
effect was present: 07o, up to 307o and larger than
30%. The categorizations were compared among
the three treatment groups using Fisher's exact test.
Six-month follorn-up
The 6-month pain data were analyzed using the
Statistical Package for the Social Sciences (version
16.0 for Windows, SPSS Inc., Chicago, IL). Ordinal
variables were compared using the non-parametric
Kruskal-Wallis test for independent samples. Ca-
tegorical variables were analyzed using Fisher's
exact test.
Results
Recruitment and retention of patients
Figure L shows the flow chart outlining the recmit-
ment and retention of study patients.
Overall, 439 patients were screened for recruit-
ment into the trial between May 2006 and April
2008. Of these,1,21 did not meet the inclusion criteria
(34 were older than 75 years of age,29 had diabetes
and/or an elevated creatinine, 16 declared an al-
lergy to one of the study medications, 12 had a
history of being on chronic pain medications, 11
presented with a psychiatric disordeq, nine had a
BMI > 45, five were not proficient in English and five
had rheumatoid arthritis). Of the 318 patients who
were eligible to participate, 1.26 patients were ran-
domized to one of the three study groups. One
hundred and fourteen patients completed the in-
hospital protocol. The reasons for not completing
the in-hospital protocol were cancellation of surgery
after taking the pre-operative medications (n:4),
patients who requested withdrawal from the study(n:2), patients who received general anesthesia
(n:2), failure of the spinal anesthetic (n:1), sw-
geon withdrawal of patient (n:"1) and one patient
who had a more extensive surgical procedure per-
formed (n:1) (see Fig. 1).
Six months after surgery, S2 (71,.9Vo;5"1. male,3'1.
female) patients were followed up.
Fig.L. FIow diagram of patient distribution.
Tablel
Between the in-hospital intervention and 6-
month follow-up, 20 patients were lost to follow-
up (unable to be contacted) and 12 refused to be
interviewed. Of the 82 patients who were followed
up,2B,2B and 26 patients were in groups 1.,2 and3,
respectively.
Demographic and clinical uariables
Table 1 shows the demographic and clinical vari-
ables describing the sample of 717 patients. The
groups were comparable with respect to age, gen-
der, BMI, ASA status and duration of surgery.
In-ho spit aI int era ent io n
Overall significant differences arnong the three
groups (G1 : Placebo, G2: Preemptive GPN and
G3: Post-operative GPN) were not found (P:
0.53) in morphine consumption over the first 48
post-operative hours (Fig. 2). The group x time
interaction effect (measuring possible differences in
the rates of consumption) was not significant (P:
0.09). Likewise, pain scores did not differ signifi-
cantly at rest (P :0.49) or with movement (P:
0.91) over the first a8h (Fig. 3). The group r time
interaction was not significant for rest or move-
ment pain scores (P :0.94 and 0.11, respectively).
On post-operative day 1, there was no difference in
pain scores upon moving from the lying to the
sitting position at the edge of the bed (G1 : 39.4 +
25.8, G2:40.3 *22.0 and G3 :38.7 +24.il (mean
+ SD) (P:0.89). Finally, the three groups did not
differ significantly with respect to sedation (P:
0.51), nausea (P :0.95), vomiting (P :0.2), pruritus
(P :0.79) or dizziness (P: 0.84) (Table 2).
Six-month chronic pain follow-up
Six months following THA surgery, neither the
incidence of chronic post-surgical pain nor anxiety
or depression scores differed significantly among
the groups (all P>0.05). Of the 82 patients who
Assesed tbr eligibility
(n=439)
Excluded
Age greater than 75 (n=34), Diabetes and/or an
elevated creatinine (n=29)- Allergy to a study
medicarion {n=16). History ofchrnnic pain 0r=12).
Psychiatric disorder (n=l t), BMI > 45 (n=9),
I.anguage Bilder (n=5). English, Rheumaroid
Arthitis (n=5), Declined participaiion {n=162)
Randomized
(n=l 26)
Group lI
GPN 600rng/Placebo
(n=42)
Group III
Placebo/GPN 600ng
(tt=4?)
Excluded:
I pt 
- 
Given a
General Anesthetic
I pt 
- 
Surgeon
pulled from study to
stalt non protocol
medication
I pt 
- 
Failed spinal
anesthetic. given
General Anesthetic
I pt 
- 
no PCA data
recorded
Excluded:
2 pts - cancelled
sugeries aller
preoperative
medication given
2 pts 
- 
requested
withdrawal on POD I
Excluded:
2 pts - cancelled
surgeries after
preoperatrve
medication given
I pt - enrolled but had
more extensrve
snrgery (i.e. revision.l
I pt 
- 
received a
General Anesthetic
6 month follow up
1n =28)
6 month follow up
(n 
=28)
Demographic characteristics and duration of surgery.
Variable (Gl ) Placebo/Placebo (n: 39) (G2) GPN 600/Placebo (n:  0) (G3) Placebo/cPN 600 (n : 38)
Age (year)
Gender (M/F)
Body mass index (BMl)
ASA (r/il/|il)
Duration of surgery (min)
61 .3 + 10.7
21/18
29.2 +5.3
5/28/6
73.8 +22.7
58.9 + 9.4
27/11
29.2 + 5.4
6/28t6
76.0 + 19.8
60.4 + 8.1
22/16
29.0 + 6.3
7/26/5
70.9 + 15.0
Data are mean + SD. No significant differences were observed among groups.
Table2
Side effect profiles.
e40
€)
E.o
20
Percent of time (G1)
patient experienced Placebo/
Placebo(n: 38)
(G2) (G3)
GPN 600/ Placebo/Placebo GPN 600(n: 38) (n: 38) -
10
Sedation
0% sedation
<30% sedation
>30% sedation
Nausea
07o nausea
<30% nausea
>30% nausea
Pruritus
0% pruritus
<30% pruritus
>30% pruritus
Dizziness
0% dizziness
<30% dizziness
>30% dizziness
Vomiting
0% vomiting
<30% vomiting
31
7
0
24
13
1
28I
2
30I
0
31
7
31
6
I
26
11
I
31
6
'l
31
7
1
31
7
27
10
1
26
11
1
27
2
27
10
1
36
2
E
e40
o
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Eso
'6
o- 
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Fig.2. Cumulatiue morphine consumption after total hip arthro-
plasty. Oaerall, no significant diffuenccs were found among the
three groups (G1 
-- 
PlacebolPlacebo, G2: Preemptioe GPNlPla-
cebo and G3: PlacebolPost-operatiae GPN) in morphine con-
sumption ooer the first 48 post-opuatfue hours (P:0.53).
VAS-M
o12243648
Hours After Surgery
Fig.3. Pain scores at rest and with moaement aftu total hip
arthroplasty (Gl : PlacebolPlacebo, G2 : Preemptioe GPN lPIa-
cebo and G3: PlacebolPost-operatiae GPN). Pain scores did not
differ at rest (P : 0.49) or with moaement (P :0.97,) ooer the first
48h.
were interviewed at 6 months,3l (37.87o) patients
reported chronic pain related to their hip arthro-
plasty (i.e. 27% of the entire study cohort). The
characteristics/severity of the pain described by
the 31 patients who reported pain (G1 : 1,0, G2: '1,2
and G3 :9) are shown in Table 3. The average pain
scores reported at 6 months were <4/70 and
appeared to have minimal impact on daily func-
tioning. Pain scores at 'the worst' were in the
moderate range (G1 : 4.2 +2.9, G2:4.7 L2.2 and
G3:4.9 +2.2) (P :0.61).
"lndicates significant difference P<0.05.
Discussion
Gabapentin has been efficacious in reducing
opioid consumption after many types of sur-
gery.a's'e'tns'18 i\4eta-analyses harre ib*onstrated
that this anticonvulsant leads to a reduction in
post-operative opioid use and a reduction in post-
operative pain scores.slss The results of the pre-
sent study demonstrate that a 600 mg dose of
gabapentin, whether administered pre-operatively
or post-operatively, in the context of a robust multi-
modal analgesia regimen with spinal anesthesia,
does not reduce post-operative opioid consump-
tion or pain scores (Figs 2 and 3). Given the recent
increase in the use of gabapentin within the peri-
operative setting, this novel work examines the
potential added benefit of a single preemptive
dose to an already clinically robust pain regimen.
When compared with the current gabapentin lit-
erature, this trial has a larger sample size than most
studies published thus far. Therefore, our results
question the addition of a single dose of gabapentin
to an already satisfactory clinical regimen. How-
ever, gabapentin continued into the post-operative
period has been found to be beneficial for move-
ment-evoked pain in other patient populations4s
and may also be beneficial with respect to post-
arthroplasty rehabilitation. The potential benefit of
the gabapentinoids on improving inpatient rehabi-
Table3
Six-month pain profile (patients with chronic pain only).
(Gl) Placebo/Placebo
(n = 10 of 28 patients
reported chronic
post-surgical pain)
(G2)GPN 600/Placebo(n: 12 of 28 patients
reported chronic
post-surgical pain)
(G3) Placebo/GPN 600
(n = 9 of 26 patients
reported chronic
post-surgical pain)
Total hip afthroplasty follow-up pain questionnaire
How often do you have pain at your adhroplasty
site?
Measurement of allodynia: number of patients who
reported that running their finger along their scar is
painful.
Measurement of hyperalgesia: number of patients
who reported that lifting their knee to 90" hurt or felt
uncomfortable.
Usual intensity of your post hip arthroplasty site
pain (0-10)
The worst intensity of your post hip arthroplasty site
pain (0-10)
The extent to which your post hip adhroplasty site
pain interferes with your everyday activities (G-10)
Neuropathic pain scale items
Q.1 How intense is your pain
Q.2 How sharp your pain feels
Q.3 How hot your pain feels
Q.4 How dull your pain feels
Q.5 How cold your pain feels
Q.6 How sensitive your skin is to light touch or
clothing
Q.7 How itchy your pain feels
Q.8 How unpleasant your pain feels
Q.10a How unpleasant is your deep pain.
Q.10b How unpleasant is your superficial pain
Hospital anxiety and depression scores
Anxiety score
Depression score
Constant:2
Periodic: 5
Brief: 3
2
3
3,4 + 1.6
5.6 + 3.1
3.9 * 3.3
3.6 + 1.9
2.2+2.3
0.9 + 1.9
3.3 + 2.9
0.3 + 0.9
1.6 + 2.8
0.0 + 0.0
3.7 +2.6
4.0 +2.8
1.4 t 1.4
Constant: 4
Periodic: 5
Brief: 3
I
3
3.1 + 1.9
4.6 + 1.9
3.6 + 3.6
2.9 + 1.7
2.1 +2.7
o.2 r 0.4
2.0 +2.5
1.0 + 2.0
0.5 + 1.0
0.8 * 1.6
3.7 +2.7
2.9 +2.4
0.9 + 1.0
5.1 + 2.6
3.1 + 2.9
Constant: 1
Periodic: 4
Brief: 4
0
4
3.1 + 1.5
5.3 + 2.1
4.1 + 3.6
3.9 + 2.6
2.4 + 1.9
0.6 + 1.1
3.0 +2.2
0.0 + 0.0
0.3 + 1.0
0.1 + 0.3
3.1 + 3.2
3.9 r 2,5
0.3 * 1.0
3.0 + 2.3
5.1 + 5.4
5.8 * 3.0
4.0 + 3.0
Data are mean + SD. No significant differences were observed among groups. PACU, post-anesthetic care unit.
litation throughout the peri-operative stay is cur-
rently under investigation and a recent publication
has shown promising results with improvement in
active assisted knee flexion after total knee arthro-
plasty.6 Recent studies looking at gabapentin in
association with regional anesthesia techniques
have yielded mixed results. A recent study by
Turan et a1.22 showed that gabapentin (1200mg
day) as an adjunct to epidural analgesia decreased
pain and analgesic consumption in patients who
had undergone lower extremity surgical proce-
dures. In a second study by the same group,'o the
same dose of gabapentin administered pre-opera-
tively decreased tourniquet-related pain and im-
proved the quality of anesthesia during hand
surgery under intravenous regional anesthesia. In
contrast, Adam et al.'" found that a single pre-
operative dose of 800m9 of gabapentin did not
augment post-operative analgesia in patients given
interscalene brachial plexus blocks for arthroscopic
shoulder surgery. Similarly, Brogly et al.s6 recently
demonstrated that patients undergoing a thyroi-
dectomy and receiving a single preemptive dose of
1200mg of gabapentin within the context of cervi-
cal plexus blocks did not experience a reduction in
acute pain or opioid consumption. However, a
single 1200 mg dose of gabapentin did prevent
delayed neuropathic pain at six months compared
with the patients who received placebo.'o It is clear
that gabapentin in conjunction with regional an-
esthesia regimens, needs further investigation with
respect to the timing and the duration of adminis-
tration post-operatively.
The results of the present study indicate that the
rationale for using a single pre-operative dose of
gabapentin in the context of regional anesthesia
should be questioned. Unless gabapentin signifi-
cantly modifies central sensitization in the long
term, the addition of a single preoperatiae dose
in conjunction with regional blocks seems to be
somewhat redundant. Given the ability of local
anesthetics to completely block pain and decrease
morphine consumption in the acute post-surgical
time period, the addition of a single pre-operative
dose will likely not further reduce pain or opioid
consumption as demonstrated by our results and
others.16's6 However, starting gabapentin pre-
operatively and continuing this medication into
the post-operative time period could lead to an
opioid-sparing effect and may reduce pain with
functional recovery and rehabilitation.a'6 Gaba-
pentin has been investigated as an adjunct to
rehabilitation due to its efficacy in reducing move-
ment-evoked pain.ffi '1 3'1's'23'26'28
Pandey et ai.18 randomized patients undergoing
lumbar discectomy to receive a one-time dose of
either placebo or gabapentin 300, 600, 900 or
1200mg pre-operatively. The optimal dose was
600mg; at higher doses (900 and 1200mg), patients
exhibited more side effects with no additional
reduction in pain. At our institution, patients who
received > 600 mg of gabapentin before surgery as
part of daily clinical practice demonstrated an
increased incidence of sedation. Using a design
similar to that of the present study, and using the
same patient population, Mathiesen et al."' rando-
mized 120 patients to either (A) placebo, (B) prega-
balin 300mg or (C) pregabalin 300mg and
dexamethasone Bmg before THA. All patients
also received acetaminophen L g and a standar-
dized spinal anesthetic before surgery. After 24h,
morphine consumption was significantly reduced
in groups B and C compared with group A. There
are differences between the present study and that
of Mathiesen and colleagues. First, the bioequiva-
lent dose of 300mg pregabalin is approximately
1800 mg of gabapentin (6: 1), which would be three
times the dose used in our trial (which also demon-
strated increased sedation). Second, Mathiesen and
colleagues did not use a COX-2 antagonist as part
of their pain regimen. It is clear that more work
needs to be carried out with regard to the optimal
dosing of gabapentin in various surgical popula-
tions and the determination of the efficacy at
treating post-operative pain beyond the immediate
24 or 4Bh of surgery.
Most trials thus far have compared gabapentin
with placebo. Gilron et al." and Turan et al.'"
published studies in which they administered Ga-
bapentin and Cox II inhibitors, and compared with
each agent in isolation. Both studies demonstrated
a superior opioid-sparing and pain-reducing effect
in patients who received the multimodal interven-
tion. Our multimodal regimen involved spinal
anesthesia (bupivacaine), a COX-2 antagonist (cel-
ecoxib), acetaminophen and a steroid (dexametha-
sone). Using the above multimodal regimen, we
likely established an gffective level of preemptive
analgesia before the surgical injury, and then con-
tinued the effective analgesic level well into the
post-injury period to prevent central sensitization
during the immediate post-operative time period.
The pain scores were excellent throughout our trial
(Fig. 3). Regardless of the intervention (gabapentin
administration before or after surgery or placebo),
patients reported pain scores in the mild range(<4/10) at rest, with movement and while moving
from lying to sitting on POD1. It is clear that the
single dose of gabapentin had no effect on an
already robust peri-operative pain regimen.
Six months following THA surgery, the inci-
dences of chronic post-surgical pain, anxiety and
depression scores were similar across groups. Of
the 82 patients who were reached via a telephone
interview, 31 patients (37,8%) reported chronic pain
related to their hip arthroplasty. It has been sug-
gested that the severity of acute pain may be related
to the development of chronic pain.l's8'se Other
mechanisms underlying the transitio-n to chronicity
may involve ectopic neural activity,6u psychological
factors"' and genomics."'Forty percent (40%) of the
patients in the present study reported post-surgical
pain at 6 months notwithstanding the mild acute
pain intensity experienced in the days after surgery.
At the 6-month interview, the usual intensity of the
pain was <4/1.0 across all groups and the pain did
not interfere significantly with their daily activities.
It is important to note that this study was powered
for acute pain outcomes; even though we were able
to contact 71% of patients post-operatively, the
possibility remains that this study may be under-
powered to detect group differences with respect to
the intensity of chronic post-surgical pain. The
incidence of chronic post-surgical pain at 6 months
(37.8%) may be an over-estimate of the true inci-
dence because it is possible that mainly patients
with chronic pain agreed to be followed up. Using
the entire cohort as the denominator yielded a
lower estimate (27Vo) of the incidence, which re-
mains higher than expected.
This study has several limitations. First, the
optimal dose of preemptive gabapentin has not
been elucidated in hip arthroplasty patients. It is
unlikely that giving even higher doses of this
anticonvulsant in the context of regional anesthesia
would change the observed outcome in the context
of regional anesthesia techniques (spinal blockade,
peripheral blocks, etc.) because the half-life of a
single dose of gabapentin (i.e. G8 h) often does not
outlast the effective times of the regional anesthetic.
The present results are specific to our multimodal
analgesic design and cannot be generalized to the
same surgery and other surgeries performed under
feneral anesthesia. Second, even though the inci-
dence of chronic pain seen in this study is higher
than reported elsewhere in the literature," the
severity and impact on patient functioning appears
to be minor (Table 3). Another limitation is that we
did not assess the incidence or the intensity of pain
before surgery. Given that the majority of patients
undergoing TFIA have significant levels of pain
and disability before surgery,o'it is quite possible
that the 37.870 (who reported mild pain 6 months
after surgery) represents an improvement relative
to their pre-operative pain and functioning. Future
sfudies examining the course of pain over time
should collect baseline pre-operative data.
In conclusiory a single 600mg dose of gabapen-
tin, whether given pre-operatively or post-opera-
tively, did not reduce morphine consumption or
pain scores in hospital or at 6 months post hip
arthroplasty. Gabapentin administration, in con-
junction with regional anesthesia and multimodal
regimens, requires further investigation with re-
spect to the timing and the duration of administra-
tion post-operatively.
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